June 12, 2018
The Global Evaluation of Microbicide Sensitivity (GEMS) project has developed a toolkit focused on HIV drug resistance within PrEP rollout programs. These toolkit materials are designed to help policymakers, health care workers, and laboratory personnel develop and implement drug resistance monitoring programs. New materials will be added, so be sure to visit the GEMS website frequently. PrEP… Read more »
December 20, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Drug resistance testing in Kenya progresses. Drug resistance testing in South Africa planned. Collaboration in Zimbabwe begins. GEMS to offer technical assistance on drug resistance testing. Oral… Read more »
September 13, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Drug-resistance testing in Kenya progresses. GEMS prepares for drug-resistance testing in South Africa and Zimbabwe. Genital swabs testing begins and assay development is underway. Oral PrEP modeling continues. Drug-resistance testing in Kenya progresses. The GEMS team… Read more »
June 7, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Oral PrEP modeling completed. Collaboration in Kenya continues. Resources being developed for training and M&E. Genital swabs testing begins and assay development is underway. In collaboration with… Read more »
February 27, 2017
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Genital swabs testing begins and assay development is underway. Initial oral PrEP modeling completed. Collaboration in Kenya and Namibia continues. Genital swabs testing begins and assay development is underway. GEMS has collaborated with Partners PrEP and… Read more »
November 18, 2016
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Collaboration in Kenya and South Africa moves forward. Oral PrEP modeling continues. Study concept sheets approved. Cost-effective strategies for HIV drug resistance surveillance continues. Collaboration in Kenya and South Africa moves forward. The GEMS team began… Read more »
August 26, 2016
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Specimen and data collection makes progress. Collaboration underway with other projects. Country work continues. Lab team moves forward. Specimen and data collection makes progress. GEMS received approval from the Partners PrEP Study to obtain vaginal swab… Read more »
May 6, 2016
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Information from PrEP trials and demo projects gathered. Model assumptions analysis ongoing. Policy and implementation steering committee convened. Country-specific PrEP guidance reviewed. Determination of sample collection methods underway. Information from PrEP trials and demo projects gathered…. Read more »
February 5, 2016
GEMS informs policies and defines programmatic considerations related to use of ARV-based HIV prevention products and risk of resistance. Project start-up begins. Project start-up begins. GEMS organized project teams, activated stakeholders and partners, and set up communications. The lab team requested PrEP trials’ samples for assay development work. The modeling team is adapting the current… Read more »